/

Empresas

Ni

No verificado

NiKang Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

4 Comunicados de prensa

Ver todos los comunicados de prensa

08/09/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader

Fuente

NiKang Therapeutics

Editor

1.00

0

10/03/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 Degrader

Fuente

NiKang Therapeutics

Editor

1.00

0

21/01/2025

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma

Fuente

NiKang Therapeutics

Editor

1.00

0

09/09/2024

Eventos

Ferias y Congresos

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

NiKang Therapeutics® to Present Preliminary Results of Phase 1/2 Clinical Trial of NKT2152 in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma at ESMO 2024 Congress

Fuente

NiKang Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0